Inventors
Sophie AGAUGUE, Paul Frohna
Assignees
Imcheck Therapeutics
Abstract
It is disclosed BTN3A inhibitory antibodies for use in treating gastro-intestinal inflammatory disorders, such as inflammatory bowel disease. The disclosure more specifically relates to specific anti-BTN3A antibodies that specifically bind to BTN3A and inhibit the degranulation of Vγ9/Vδ2 T cells and their use in the manufacturing of novel drugs for use in treating gastro- intestinal inflammatory disorders such as ulcerative colitis and Crohn’s disease.